Researchers Identified New Cancer Immune Checkpoint
A newly found protein circuit in human tumors limits the effectiveness of radiation-based cancer therapies.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Do you trust that new medical research discoveries will reliably improve cancer treatment options for patients?
Scientists have identified an immune checkpoint mechanism involving FXR, TRIM22, and STAT1 that suppresses tumor immunity after radiation. This pathway explains why human tumors often show less immune activation than those observed in mice.
Why it matters
The FXR-TRIM22-STAT1 circuit dampens the body's interferon response to radiation, effectively shielding cancer cells. Understanding this pathway provides a potential strategy to boost the impact of cancer radioimmunotherapy.
Researchers found that ionizing radiation stabilizes the FXR protein, which subsequently induces the E3 ligase TRIM22 to degrade STAT1. This degradation process effectively suppresses critical interferon-stimulated gene programs in human tumors.
The players
FXR
This nuclear receptor is stabilized by ionizing radiation and acts as a key component in suppressing tumor immunity.
TRIM22
This E3 ligase is induced by FXR and catalyzes the degradation of the STAT1 protein.
STAT1
This protein is essential for interferon-stimulated gene programs that mediate the body's immune response.
Ursodeoxycholic acid
This substance acts as an FXR antagonist that can restore immune signaling in laboratory models.
The details
The study revealed that while murine tumor cells lack the specific TRIM22 family member required to destabilize STAT1, human tumors utilize this circuit to inhibit immune responses. Ursodeoxycholic acid, a known FXR antagonist, was shown to suppress TRIM22 and restore STAT1 signaling in humanized mouse models.
Timeline
September 30, 2026: The research findings were published.
The Big Picture
This study identifies a biological bottleneck that limits the success of the development of radioimmunotherapy. The findings suggest that targeting specific protein interactions can overcome resistance patterns observed in clinical radiation treatments.
The identification of this immune pathway offers a potential path to improve the efficacy of standard radiation treatments. Future clinical applications could involve combining current radiotherapy with FXR antagonists to enhance patient immune responses against tumors.
The takeaway
This discovery highlights how human-specific immune pathways create resistance to conventional cancer therapies. By modulating these internal circuits, researchers hope to turn radiotherapy into a more potent tool for inducing durable anti-tumor immunity.
Further reading
For more on the current state of cancer treatment research, explore the Cancer section.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that new medical research discoveries will reliably improve cancer treatment options for patients?
